ClinicalTrials.gg
Not yet recruitingNCT07705984Updated Jul 15, 2026

Kinesio Taping for Neurogenic Bowel Dysfunction in Spinal Cord Injury

An interventional study of Kinesio Taping and Routine Bowel Management Program in Neurogenic Bowel Dysfunction and Spinal Cord Injury, sponsored by Pamukkale University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Pamukkale University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Neurogenic bowel dysfunction is a common complication of spinal cord injury and may cause constipation, difficulty with defecation, prolonged bowel care, incomplete evacuation, fecal incontinence, and reduced quality of life. This randomized controlled trial aims to evaluate the effectiveness of Kinesio Taping added to a routine bowel management program in adults with spinal cord injury and upper motor neuron-type neurogenic bowel dysfunction.

Thirty participants will be randomly assigned to one of two parallel groups. The control group will receive a routine bowel management program, while the intervention group will receive Kinesio Taping in addition to the routine bowel management program. Kinesio Taping will be applied to the lower abdominal and lumbosacral regions three times per week for 4 weeks.

The primary outcome will be defecation frequency recorded using a 7-day bowel diary. Secondary outcomes will include stool consistency, defecation duration, perceived constipation severity, neurogenic bowel dysfunction severity, and health-related quality of life. Assessments will be performed before and after the 4-week intervention.

02

Conditions studied

  • Neurogenic Bowel Dysfunction
  • Spinal Cord Injury

Keywords

  • Kinesio Taping
  • Neurogenic Bowel
  • Constipation
  • Bowel Management
  • Spinal Cord Injury Rehabilitation
03

In context

Spinal Cord Injuries

2,025 studies on the registry are indexed under Spinal Cord Injuries; 537 are open to participants now.

This study's planned enrollment of 30 is above the median of 24 across 1,633 interventional studies indexed under Spinal Cord Injuries.

Browse Spinal Cord Injuries studies →

Lead sponsor

Pamukkale University is the lead sponsor of 342 studies on the registry; 61 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older with traumatic or nontraumatic spinal cord injury
  • Neurological level of injury at T12 or above
  • Upper motor neuron-type neurogenic bowel dysfunction
  • Duration of spinal cord injury longer than 6 months
  • Ability and willingness to provide written

Exclusion criteria

Exclusion Criteria:

  • Age younger than 18 years
  • Neurological level of injury below T12
  • Gastrointestinal disease diagnosed before the spinal cord injury, including irritable bowel syndrome or inflammatory bowel disease
  • History of conservative treatment for neurogenic bowel dysfunction within the previous 6 months
  • Colostomy or history of bowel surgery
  • Neurological disease other than spinal cord injury that may cause gastrointestinal or anal sphincter dysfunction
  • Cognitive impairment that may interfere with participation in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Routine Bowel Management Program

    Participants in this arm will receive an individualized routine bowel management program based on their clinical condition for 4 weeks. The program may include scheduled bowel care, dietary and fluid recommendations, appropriate positioning, physical activity, abdominal massage, rectal evacuation techniques, suppositories, enemas, and oral or rectal laxatives when clinically indicated. Participants will be instructed not to change their usual dietary habits during the study period.

    Behavioral: Routine Bowel Management Program

  • Experimental
    Kinesio Taping Plus Routine Bowel Management Program

    Participants in this arm will receive Kinesio Taping in addition to the routine bowel management program for 4 weeks. Kinesio Taping will be applied to the lower abdominal and lumbosacral regions three times per week by the same experienced physician. The tape will remain in place for 2 days and will be removed before the next treatment session. A star-shaped correction technique will be applied to the lumbosacral region with 25%-50% tension, and an I-shaped correction technique will be applied to the lower abdominal region between the right and left anterior superior iliac spines. No tension will be applied to the ends of the tape

    Other: Kinesio Taping · Behavioral: Routine Bowel Management Program

Interventions

  • OtherKinesio Taping

    Kinesio Taping will be applied to the lower abdominal and lumbosacral regions three times per week for 4 weeks. The tape will remain in place for 2 days and will be removed before the next treatment session. A star-shaped correction technique will be applied to the lumbosacral region with 25%-50% tension. An I-shaped correction technique will be applied to the lower abdominal region between the right and left anterior superior iliac spines. No tension will be applied to the ends of the tape.

  • BehavioralRoutine Bowel Management Program

    Participants will receive an individualized routine bowel management program based on their clinical condition for 4 weeks. The program may include scheduled bowel care, dietary and fluid recommendations, appropriate positioning, physical activity, abdominal massage, rectal evacuation techniques, suppositories, enemas, and oral or rectal laxatives when clinically indicated. Participants will be instructed not to change their usual dietary habits during the study period.

06

What researchers measure

Primary outcomes

  1. Change in Defecation Frequency

    Defecation frequency will be recorded using a 7-day bowel diary and expressed as the total number of defecations during a 7-day period. Higher values indicate more frequent bowel movements.

    Time frame: Baseline and at the end of the 4-week intervention

Secondary outcomes

  1. Change in Bristol Stool Form Scale Score

    Stool consistency will be assessed using the 7-point Bristol Stool Form Scale. Type 1 indicates separate hard lumps, while Type 7 indicates entirely liquid stool. Types 3 to 5 generally represent softer or more desirable stool consistency.

    Time frame: Baseline and at the end of the 4-week intervention

  2. Change in Perceived Constipation Severity

    Participants will rate the overall severity of constipation on a 10-cm Visual Analog Scale ranging from 0 to 10. A score of 0 indicates no constipation, while a score of 10 indicates very severe constipation.

    Time frame: Baseline and at the end of the 4-week intervention

  3. Change in Neurogenic Bowel Dysfunction Score

    Neurogenic bowel dysfunction severity will be assessed using the 10-item Neurogenic Bowel Dysfunction Score. The total score ranges from 0 to 47, with higher scores indicating more severe neurogenic bowel dysfunction.

    Time frame: Baseline and at the end of the 4-week intervention

  4. Change in Short Form-36 Health Survey Scores

    Health-related quality of life will be assessed using the 36-item Short Form Health Survey. The instrument includes eight subscales, each scored from 0 to 100. Higher scores indicate better perceived health status.

    Time frame: Baseline and at the end of the 4-week intervention

  5. Change in Defecation Duration

    Defecation duration will be recorded in minutes using a 7-day bowel diary. Participants will record the time required to complete each bowel evacuation. A shorter duration indicates less time spent on bowel care.

    Time frame: Baseline and at the end of the 4-week intervention

  6. Change in the Feeling of Complete Evacuation

    The feeling of complete bowel evacuation will be recorded in the 7-day bowel diary after each defecation. The outcome will be expressed as the number or proportion of defecations associated with a feeling of complete evacuation during the 7-day assessment period. Higher values indicate more frequent complete evacuation.

    Time frame: Baseline and at the end of the 4-week intervention

  7. Change in Straining During Defecation

    Straining during defecation will be recorded in the 7-day bowel diary. The outcome will be expressed as the number or proportion of defecations accompanied by straining during the 7-day assessment period. Lower values indicate less frequent straining.

    Time frame: Baseline and at the end of the 4-week intervention

  8. Change in Painful Defecation

    Painful defecation will be recorded in the 7-day bowel diary. The outcome will be expressed as the number or proportion of defecations associated with pain during the 7-day assessment period. Lower values indicate less frequent painful defecation.

    Time frame: Baseline and at the end of the 4-week intervention

07

Study locations

1 site
08

References and documents

Publications

  • Dandinoglu T, Kaya E. Kinesio Taping in spinal cord injury rehabilitation: A scoping review. J Spinal Cord Med. 2026 Feb 12:1-9. doi: 10.1080/10790268.2026.2626116. Online ahead of print. PubMed 41677377 ↗
  • Karaaslan Y, Karakus A, Koc DO, Bayrakli A, Celenay ST. Effectiveness of Abdominal Massage Versus Kinesio Taping in Women With Chronic Constipation: A Randomized Controlled Trial. J Neurogastroenterol Motil. 2024 Oct 30;30(4):501-511. doi: 10.5056/jnm23131. Epub 2024 Jun 3. PubMed 38826075 ↗
  • Orhan C, Kaya Kara O, Kaya S, Akbayrak T, Kerem Gunel M, Baltaci G. The effects of connective tissue manipulation and Kinesio Taping on chronic constipation in children with cerebral palsy: a randomized controlled trial. Disabil Rehabil. 2018 Jan;40(1):10-20. doi: 10.1080/09638288.2016.1236412. Epub 2016 Oct 28. PubMed 27793072 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Oct 2026, 3 months later.

Of 790 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 3 months is below that.

Counting every sponsor, half of 839 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Jul 15, 2026
StartEst.
Jul 30, 2026
Primary completionEst.
Oct 30, 2026
CompletionEst.
Oct 30, 2026
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07705984
Responsible party
Meltem Gunes Akinci (Assistant Professor, Pamukkale University) — Principal investigator
First posted
Jul 15, 2026
Start date
Jul 30, 2026 (estimated)
Primary completion
Oct 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Jul 15, 2026

Study contacts

Meltem Gunes Akıncı, MD
Contact
meltem_aytekin@hotmail.com
+902582966000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion